The Effect of Smoking on Endocrine Therapy for Stage IV Hormone Receptor Positive Breast Cancer
| Autor: | Koji, Takada, Shinichiro, Kashiwagi, Rika, Kouhashi, Nozomi, Iimori, Akimichi, Yabumoto, Wataru, Goto, Yuka, Asano, Yukie, Tauchi, Tamami, Morisaki, Masatsune, Shibutani, Hiroaki, Tanaka, Masaichi, Ohira |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Anticancer Research. 42:3937-3946 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.15888 |
| Popis: | Smoking worsens breast cancer prognosis. It has been reported that tobacco components directly reach the mammary gland tissue, causing smoking-related DNA damage and biological effects. We hypothesized that smoking may have characteristics that affect the therapeutic effect and clinical course in patients with stage IV hormone receptor-positive breast cancer (HRBC) who received endocrine therapy as the first-line treatment.Fifty-six patients diagnosed with stage IV HRBC were treated with endocrine therapy as the first-line treatment. Before treatment, the period and amount of smoking were confirmed through patient interviews, and each pack-year was recorded.Disease progression with new metastases was more frequent in smokers than non-smokers during endocrine therapy as first-line treatment (p=0.034). Furthermore, as the pack-year increased, new metastases tended to appear [pack-year ≤15; hazard ratio (HR)=1.929, p=0.507; pack-year 15-30, HR=3.857, p=0.223; pack-year30, HR=7.714, p=0.028].In stage IV HRBC, smoking increases the metastatic potential of breast cancer, suggesting that changes in its biology may lead to poor prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|